Daxor Corp.

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN.

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.   The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

Oak Ridge, TN, Nov. 14, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Daxor. In addition, Daxor intends to grant the underwriter in the offering a 45-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Daxor Corporation Announces Launch of Proposed Underwritten Public Offering

Evidence Presented Utilizing Daxor's BVA-100 ® Blood Volume Test

Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting

The Premier Event For The Cardiovascular Industry's Leading Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and Patient-Care Outcomes

DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL'22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100®)

Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group - Data Presented at Key Scientific Meeting

New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care

Compelling New Patient Outcome Data to be Presented

Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America

Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will attend the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.

Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference

Daxor Corporation (NASDAQ:DXR ) Q2 2022 Earnings Conference Call August 25, 2022 4:30 PM ET Company Participants Scott Gordon - President and Co-Founder of CORE IR Michael Feldschuh - CEO & President Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Edward Wu - Ascendiant Capital Michael Samuels - Berthel Fisher Operator Good afternoon, and welcome to the Daxor Corporation First Half 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode.

Daxor Corporation (DXR) Q2 2022 Earnings Call Transcript

Conference Call to be held today at 4:30 p.m. Eastern Time

Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022

Conference Call to be held on the same day at 4:30 p.m. Eastern Time

Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update

New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer

DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE

Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Health (NIH) Intramural Research Program-sponsored study titled “An Observational Study of Neurologic Function after COVID-19 Infection” utilizing Daxor's BVA-100 (Blood Volume Analyzer, “BVA”) technology. The study is being conducted under the leadership of Avindra Nath, M.D. at the National Institute of Neurological Disorders and Stroke (NINDS) located in Bethesda, Maryland.

Daxor's Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL.

Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference

Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will present at Maxim Group 2022 Virtual Growth Conference to be held March 28-30, 2022, 9:00 AM - 5:30 PM ET. The conference will feature a company presentation, fireside chats, roundtable discussions, and live Q&A with Mr. Feldschuh moderated by Maxim Research Analysts.

Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference

Daxor 's BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure

Study Demonstrates Importance and Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure

Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022

Daxor Corporation Commences Trading on The NASDAQ Capital Market

Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD, MPA to its Board of Directors, effective January 18, 2022.

Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange - American. Daxor's common stock will continue trading under the ticker symbol “DXR” after the transfer. The Company's common stock will continue to trade on the NYSE American until the market closes on February 1, 2022.

Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022

Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions

DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

The SBIR/STTR Matching Fund Grant Will Advance the Company's Innovation and Commercialization Efforts, and Job Creation

Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee

Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing Appropriate, Personalized Care to Patients with Heart Failure

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Oak Ridge, TN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Daxor Corpor a tion (NYSE:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.

Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Company forecasts further increase in sales driven by new distributor agreements

Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021

The stock price of Daxor Corporation (NYSE MKT: DXR) increased by over 16% pre-market. This is why it happened.

DXR Stock Price Increases Over 16% Pre-Market: Why It Happened

Data Led to Multi-Center Study In Progress At Three Leading Hospitals

Daxor's Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

News for Daxor Corp. Stock (DXR)